Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

IAG H1 earnings surge amid 'robust' travel demand

(Sharecast News) - British Airways owner International Consolidated Airlines Group posted a strong set of H1 results on Friday, with "robust" travel demand and operational improvements boosting profitability. IAG said revenue had risen 8% year-on-year to €15.91bn in the six months ended 30 June, while operating profits before exceptional items surged 43.5% to €1.88bn. Adjusted earnings per share jumped nearly 70%.

The FTSE 100-listed group cited favourable fuel costs, foreign exchange tailwinds, and a strong performance across its core brands and geographies as key drivers of H1 growth.

Margins improved by 2.9 percentage points to 11.8%, supported by IAG's transformation programme and cost discipline, while net debt fell to €5.46bn, with leverage down to 0.7x EBITDA.

British Airways, Iberia, and Aer Lingus all contributed to profit growth, with Iberia benefiting from higher unit revenue and increased MRO income. Vueling, on the other hand, saw a slight decline, reflecting softer intra-Europe demand.

Looking ahead, IAG said it remains confident in delivering FY earnings growth and margin progression, despite ongoing geopolitical and macroeconomic uncertainty.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.